ea0025p81 | Clinical biochemistry | SFEBES2011
Majumdar Kalpita
, Aditya B S
Introduction: Hyponatraemia is common biochemical abnormality in hospitalised patients and is difficult to manage in some cases. Tolvaptan is presently licensed in the UK for the treatment of hyponatraemia secondary to SIADH. We present our experience of using Tolvaptan.Cases: Patient 1 was admitted with sagittal sinus thrombosis. Over 9 days serum sodium dropped from normal to 121 mmol/l with biochemical evidence of SIADH. The patient was treated with T...